The emergence of immunocompromising diseases such as HIV/AIDS or other 32 immunosuppressive medical conditions have opened an opportunity for fungal infections to 33 afflict patients globally. An increase antifungal drug resistant fungi have posed a serious threat 34 to patients. Combining these circumstances with a limited variety of antifungal drugs available to 35 treat patients has left us in a situation where we need to develop new therapeutic approaches 36 that are less prone to development of resistance by pathogenic fungi. In this study we present 37 the utilization of the nanoemulsion NB-201 to control human pathogenic fungi. We found that 38 the NB-201 exhibited in vitro activity against C. albicans, including both planktonic growth and 39 biofilms. Furthermore, treatments with NB-201 significantly reduced the fungal burden at the 40 infection site and presented enhanced healing process after subcutaneous infections by multi-41 drug resistant C. albicans in a murine host system. NB-201 also exhibited in vitro growth 42 inhibition activity against other fungal pathogens, including Cryptococcus spp, Aspergillus 43 fumigatus, and Mucorales. Due to the nature of the activity of this nanoemulsion, there is a 44 minimized chance of drug resistance to develop, thus presents a novel treatment to control 45 fungal wound or skin infections. 46 47 48 49 50 51 52 53
Introduction 54
During the past decade there has been an exponential growth in discoveries and 55 medical advances for the treatment of human disease. This has led to better treatment for 56 patients, and as a result we have been able to prolong human life. While these recent medical 57 advances have certainly been beneficial overall, procedures such as solid organ transplants and 58 cancer treatments have left many patients in an immunocompromised state. The emergence of 59 immunocompromising diseases such as HIV/AIDS or other immunosuppressive medical 60 conditions have opened an opportunity for fungal infections to plague patients globally (1) (2) (3) (4) . 61
Candida albicans is a human commensal fungus found on the skin, mucosal 62 membranes, and the normal gut flora (5, 6) . C. albicans is known to be an opportunistic fungus 63 and the most common fungal pathogen which typically infects immunocompromised patients (3, 64 4) . Treatment for candidiasis currently relies on three major classes of antifungal drugs including 65 echinocandins, azoles, and polyenes (7, 8) . Prior to the introduction of echinocandins, 66 fluconazole was the most common drug used to treat C. albicans infections (7) . Recently there 67 has been an increase in cases of drug resistant C. albicans infections resulting in an increase in 68 morbidity and mortality of patients (4, (9) (10) (11) . One explanation for drug resistance is the 69 development of mutations in the target genes of the antifungal drug (9). Secondly the 70 overexpression of efflux pumps and multi-drug resistance genes could also lead to antifungal 71 drug resistance (9). In addition, pathogenic fungi can also form biofilms that are resistant to 72 antifungal drugs (12, 13) . Thus, it is of upmost importance to develop new therapeutic 73 approaches that are less prone to the development of resistance by pathogenic fungi. 74
Membrane disruptive nanoemulsions have been developed to control pathogenic 75 bacteria (14, 15) . One example is the nanoemulsion NB-201, which is an emulsification of 76 refined soybean oil, water, glycerol, EDTA, Tween 20, and the surfactant benzalkonium chloride 77 (BZK), which is commonly used as an antimicrobial preservative in drugs, topical antiseptic, 78 clinical disinfectant, and as a sanitation agent in the food industry (14, (16) (17) (18) . The formulation exhibited in vitro growth inhibition activity against Pseudomonas aeruginosa and in 80 vivo activity in a burnt wound animal model. Treatment of animals infected with Staphylococcus 81 aureus with NB-201 by using a murine skin abrasion wound model demonstrated the 82 therapeutic potential of this nanoemulsion formulation (19, 20) . NB-201 has also shown activity 83 against Multi-Drug Resistant S. aureus (MRSA) in a study using a porcine burnt wound model 84 (14) . The NB-201 formulation is also able to greatly reduce the inflammation of infected wounds 85 and is nontoxic to the skin making it a viable method of treatment for topical bacterial infections 86 (14). 87
In this study we present the utilization of NB-201 to control pathogenic fungi. NB-201 88 exhibited in vitro efficacy against C. albicans planktonic cells and biofilms. In addition, NB-201 89 treatments significantly reduced fungal burden at the infection site and presented enhanced 90 healing process after subcutaneous infections by C. albicans in a murine host system. NB-201 91 also exhibited in vitro growth inhibition activity against other fungal pathogens, including 92
Cryptococcus spp, Aspergillus fumigatus, and Mucorales. Fungal susceptibility against NB-201 93 was observed regardless of antifungal drug resistance. Due to the nature of the activity the 94 nanoemulsion presents, there is a minimized chance of drug resistance to develop, thus 95 presenting a novel way to control fungal wound or skin infections 96 97
Results 98
In vitro activity against Candida albicans planktonic cells and pre-formed biofilms. 99 C. albicans isolates including antifungal drug resistant strains (Table 1) were tested. 96-100 well plates were inoculated with each C. albicans strain and the NB-201 nanoemulsion (NE) 101 (10%) added in ratios ranging from 1:1-1:2048. Minimum inhibitory concentrations (MICs) were 102 determined by using a 100% killing point of the C. albicans planktonic cells collected at 1, 24, 103 48, and 72-hour post addition of NB-210 to the media (Table 2) . We observed within 1 hour, a 104 concentration of 1:512 of the NE was able to kill all the planktonic cells plated. As the incubation 105 time was increased, we observed a lower MIC was required. At 24 hours, a concentration of 106 1:1024 was able to kill all the strains plated. Within 48 hours the concentration of NB-201 107 required to kill all ten strains remained at an MIC of 1:1024. At 72 hours the MIC for 100% killing 108 of the strains plated was lowered to a concentration of 1:2048 (Table 2) . 109
The ability of C. albicans to form biofilms, which increases antifungal drug resistance, is 110 a major virulence factor observed in the clinical setting (12, 13) . To test the efficacy of NB-201 111 on C. albicans biofilms, two multi-drug resistant clinical isolates TW1 and TW17 (21) were 112 chosen. The C. albicans clinical isolates TW1 and TW17 were plated on 96-well plates and 113 allowed to form a biofilm over the course of 24 hours (PFB). We then treated these PFBs with 114 the NE added in various ratios ranging from 1:1-1:2048 followed by a second-generation 115 tetrazolium (XTT) metabolic assay (Sigma-Aldrich) (22) to measure ratio of the metabolism, 116
indicative of disruptions of the biofilms, after NB-201 treatments. Within 2 hours a NE 117 concentration of 1:32 was able to inhibit 100% of the metabolism in the TW1 clinical isolate 118 ( Figure 1 A) . At 4 hours, a concentration of 1:64 was inhibiting greater than 50% of the 119 metabolism in the PFBs (Figure 1 B) , while incubation with NB-201 at 6 hours exhibited higher 120 inhibition up to 90% at the same concentration ( Within 2 hours post addition of NB-201, a concentration of 1:16 was required for 100% 126 metabolism inhibition, while we find it important to note that a concentration of 1:32 inhibited 127 95% of the metabolism in the PFBs (Figure 1 G) . Within 4 hours of exposure to the NE the 128 PFBs presented 100% metabolism inhibition at a 1:32 concentration with >50% inhibition being 129 observed at a concentration of 1:64 ( Figure 1H ). After 6 hours of exposure, a 1:64 concentration 130 of NB-201 inhibited 80% of the metabolism in the PFBs ( Figure 1I) . A 24-hour exposure to the 131 NE at a concentration of 1:128 presented a 70% inhibition of the metabolism in the TW17 PFBs 132 while a concentration of 1:64 inhibited 100% of the metabolism ( Figure 1J ). At 48 hours of 133 exposure a concentration of 1:256 presented 85% inhibition of metabolism ( Figure 1K ) while a 134 72-hour exposure increased that to 100% inhibition at the same concentration ( Figure 1L In vivo efficacy of NB-201 was tested by using a murine subcutaneous infection model. 142
Mice were infected subcutaneously with the multi-drug resistant C. albicans isolates TW1 or 143 TW17. We then treated the mice with NB-201 via subcutaneous injection (see Material and 144 Methods). After two days of treatment with the NB-201, we euthanized the mice and collected 145 tissues at the site of infection. To measure fungal burden in the tissues, we plated the 146 homogenized tissue onto YPD agar plates and counted the colony forming units (CFU). 147
Treatment with NB-201 resulted in a significant decrease of fungal CFUs in mice infected with 148 TW1 (P=0.013) and with TW17 (P=0.002) compared to PBS-treated control groups (Figure 2A) . 149
The C. albicans strains from the first infection experiment were recovered and used for a 150 second round of the assay. In the group of mice infected with the recovered TW1 or TW17, we 151 observed a significant decrease of CFUs in the tissues of mice treated with the NE (P=0.005 or 152 P=0.004, respectively) when compared to mice treated with PBS. (Figure 2B ). These results 153 demonstrate that NB-201 has the efficacy to control C. albicans infections while the resistance 154 and/or tolerance against NB-201 is less likely to develop. The azole fluconazole still remains as 155 one of the first drugs administered for the treatment of candidiasis (23). With this in mind we 156 wanted to compare the efficacy of NB-201 to that of fluconazole. In similar fashion to our 157 previous experiment, we began by using a murine subcutaneous infection model. Mice were 158 infected with either the wild-type C. albicans SC5314, or the fluconazole resistant strain TW17 159 ( Figure 3 Following our subcutaneous model, we took tissue samples from uninfected mice, mice 166 infected with C. albicans TW17, and mice infected and treated with NB-201. We then stained 167 our tissue samples with a haemotoxylin and eosin stain. When compared to the non-infected 168 mice ( Figure 4A ), post C. albicans infection tissue presents a large collection of infiltration 169 around the hair follicles, deep dermis, and superficial fat ( Figure 4B ). After treatment with NB-170 201 we can observe a reduction in the infiltration of cells within the deep dermis, superficial fat 171 and hair follicles ( Figure 4C ). In the untreated tissue the layers of the skin are not as clearly 172 The formulation of the NB-201 was further tested to examine the ability to kill other pathogenic 181 fungi (Table 1 ) in a similar fashion to what was observed in C. albicans. We approached this by 182 inoculating 96-well plates with varying fungal strains and added NB-201 in ratios ranging from 183 1:1-1:2048. We then measured the minimum inhibitory concentrations (MIC) by using a 100% 184 killing point of the fungal strains collected at 1, 24, 48, and 72-hour post addition of NB-210 to 185 the media (Table 2) . 186
Aspergillus fumigatus 187
We performed a checkerboard assay with ten different strains of Aspergillus fumigatus including 188 drug resistant strains, all of which are known clinical isolates (Table 1) . Within one hour we 189 observed a concentration of 1:16 showed complete killing of all clinical isolates. We would like 190 to note that a concentration of 1:128 was able to kill seven out of the ten A. fumigatus clinical 191 isolates within the same timepoint ( Table 2 ). As incubation time with the NE progressed, we 192 observed a reduction in the MIC required to kill all of the A. fumigatus clinical isolates. Within 24 193 hours a concentration of 1:128 showed 100% killing of these clinical isolates (Table 2) . Finally, 194 at 48 and 72 hours all ten of the A. fumigatus clinical isolates were killed at a concentration of 195 1:512 (Table 2) . 196
Mucorales 197
We tested ten clinical isolates of varying Mucorales species (Table 1) (Table 2) . 208 209
Cryptococcus neoformans 210
Four different serotypes of C. neoformans against NB-201 were tested (Table 1) 
. Within one 211
hour an MIC of 1:1024 was able to kill all four serotypes of C. neoformans (Table 2 ). This was 212 followed by 24, 48, and 72 hours showing an MIC of 1:2048 (Table 2) 
Fungal strains and growth conditions 220
The stains used in this study are listed in Table 1 . C. albicans and C. neoformans strains were 221 grown in liquid or solid yeast extract peptone dextrose [YPD, 10 g/L yeast extract, 20 g peptone, 222 20 g dextrose, 20 g agar (for plates only)] at 30C. Mucorales were grown in potato dextrose 223 agar (PDA, potato starch 4 g/L, dextrose 20 g/L, agar 15 g/L) or yeast extract peptone glucose 224 agar (YPG, 3 g/L yeast extract, 10 g/L peptone, 20 g/L glucose, 2% agar, pH = 4.5) at 30C in 225 the light for four days. A. fumigatus strains were grown PDA at 30 C for 4 days. To collect 226 spores of Mucorales and A. fumigatus, sterile water (2 ml per plate) was added to the plate and 227 spores were collected by gently scrapping the fungal mycelial mats. 228
229
In vitro efficacy of NB-201 against C. albicans planktonic cells and biofilms. 230
Initial concentration of NB-201 was 10% for all experiments in this study besides the data in 231 supplementary table 1, where different concentration of NE was tested against A. fumigatus. 232
The C. albicans strains were inoculated at a concentration of 1x10 6 in a 96-well plate containing 233 NB-201 serially diluted in RPMI (100 l per well) ranged from 1:1 to 1:2048. 10µl samples taken 234 at 1, 24, 48, and 72 hours from each well and plated on PDA agar plates, which were incubated 235 for 48 hours. After incubation, every plate was examined for growth on the site of inoculation. 236
For biofilms, C. albicans was plated at a concentration of 1x10 6 in a 96-well plate containing 237 RPMI media and incubated for 24 hours to form a biofilm on the bottom of the wells. After 238 biofilm formation, the RPMI media was removed and the biofilms were washed with PBS. The 239 media was then replaced with media containing NB-201 serially diluted in concentrations 240 ranging from 1:1 to 1:2048. The media containing the nanoemulsion treatment was then 241 removed at 2, 4, 6, 24, 48, and 72-hour time points. The biofilms were washed with PBS and 242 stained with 0.6% crystal violet stain. The biofilms were then washed one more time with PBS to 243 remove any residual crystal violet stain. Finally, the biofilms were de-stained with 33% acetic 244 acid and 85 µl of the supernatant was transferred to a clean 96-well plate. The de-stained 245 crystal violet supernatant was then read on a plate reader and quantified. 246
In similar fashion to the crystal violet assay C. albicans was plated in a 96-well plate 247
containing RPMI media at a concentration of 1x10 6 and incubated for 24 hours to form a biofilm 248 on the bottom of the wells. After a biofilm was formed, the RPMI media was removed and the 249 biofilms were washed with PBS. The media was then replaced with media containing NB-201 250 serially diluted in concentrations ranging from 1:1 to 1:2048. The media containing the 251 nanoemulsion treatment was then removed at 2, 4, 6, 24, 48, and 72-hour time points and the 252 biofilms were washed with PBS to remove any non-adherent cells. The biofilms were then 253 treated with 100 µl of XTT solution containing 3.5 µl of menadione and incubated for 2 hours at 254 37°C. 85 µl of the supernatant was transferred to a clean 96-well plate and read in a plate 255 reader then quantified. All in vitro efficacy experiments were repeated at least twice to verify the 256 results. 257 258 Spp., C. neoformans, and A. 
In vitro efficacy of NB-201 against Mucorales

fumigatus 259
The respective fungal strains were inoculated at a concentration of 1x10 6 in a 96-well plate 260 containing NB-201 serially diluted in RPMI (100 l per well). Dilution concentrations ranged from 261 1:1 to 1:2048. 10µl samples taken at 1, 24, 48, and 72 hours from each well and plated on PDA 262 agar plates, which were incubated for 48 hours. After incubation, every plate was examined for 263 growth on the site of inoculation. 264 265
In vivo efficacy of NB-201 in a murine subcutaneous infection model 266
CD-4 mice weighing between 19-23 g were housed together. C. albicans strains 267 SC5314, TW1, and TW17 were grown in YPD liquid media, washed in PBS, and suspended in 268 PBS at a concentration of 1x10 6 . Under anesthesia, the dorsal fur of the mice was shaved. The 269 exposed skin was washed with 70% ethanol and mice were infected with 1x10 6 CFUs via 270 subcutaneous injection on the shaved dorsal side. Subsequent subcutaneous injections of NB-271 201, PBS, or fluconazole followed at 6, 24, and 48 hours. The mice were euthanized at 72 272 hours, and the skin of the infected area was collected immediately for analysis. 273
The collected mouse tissue was placed in PBS on ice then homogenized with a tissue 274 homogenizer. The homogenized tissue was then diluted 1:10 and plated on YPD agar plates 275 treated with antibiotics to prevent unwanted bacterial growth. The plates were incubated at 32°C 276 for 48 hours. The CFUs were then counted and quantified. Previously, NB-201 presented a highly effective antimicrobial potential against various 293 methicillin-resistant S. aureus strains both in vitro and in vivo (14) . The surfactant in 294 benzalkonium chloride, is a known biocide found in many over-the-counter antibacterial 295 handwipes, antiseptic creams, and other medically relevant consumer products (24). The use of 296 this surfactant in NB-201 provides the benefit of minimizing harm to the human epidermis (25), 297 as well as being an FDA approved biocide used in the clinical setting regularly. In our in vitro 298 MIC experiments with A. fumigatus we found that the presence of BZK is required for NB-201 to 299 function as a biocide. Furthermore, the presence of serum also presented an effect on the 300 efficacy of NB-201s MIC (Supplementary Table 1 ). The in vitro susceptibility test with NB-201 301 was observed on every tested fungus, with an exceptional killing efficacy observed in all four 302 serotypes of C. neoformans. 303
During our in vitro test we observed a similar trend in the efficacy of Interestingly, we observed that longer incubation times with NB-201 resulted in a lowered MIC 305 regardless of the fungal organism that was being tested. The top etymological agent of 306 candidiasis, C. albicans, still ranks amongst the leading fungal organisms to cause infection in 307 immunocompromised patients around the world and causes >50% of bloodstream infections in 308 the US (3). The biofilms produced by this fungal organism makes it intrinsically harder to treat 309 and is a growing problem and concern in the clinical setting (12, 13, 26, 27) . We found that NB-310 201 has in vitro antifungal activity against planktonic form and biofilms of C. albicans. 311 Furthermore, the in vitro activity was also observed against drug-resistant clinical isolates. In an 312 animal subcutaneous infection model, NB-201 also exhibited antifungal activity against two 313 azole-resistant strains, TW1 and TW17 (Figures 2, 3, and 4) . These results demonstrate that 314 NB-201 has anti-C. albicans activity both in in vitro and in vivo regardless of drug resistance. 315
And C. albicans is less likely to develop resistant to NB-201 ( Figure 2) . neoformans we observed a dramatic killing ability. To further confirm what we observed, we 320 employed a microscopy approach where we measured cell death with a propidium iodide stain. 321
Within 30 minutes a clear distinction of live and dead cells was observed (supplementary figure 322
2). C. neoformans is the etiological component of cryptococcosis, an infectious fungal disease 323 known to target the respiratory tract and central nervous system in humans (28) (29) (30) . Exposure to 324 C. neoformans is common amongst the general population, with majority of infectious cases 325 resulting from reactivation due to latency in cell mediated immunity (30). Despite advances in 326 modern medicine, the morbidity and mortality for C. neoformans infections remain unacceptably 327 high with mortality rates of up to 20% in infected AIDS patients (28). C. neoformans is resistant 328 to the newest antifungal drug class echinodandin. The infection mainly starts from the lungs 329 and, therefore, the aerosol treatment of NB-201 could be applied especially to lung infections. 330
Possible aerosol treatments with NB-201 could be explored in an in vivo model as a proof of 331 concept for a novel form of treatment for respiratory cryptococcosis infection. 332
Known as one of the most prevalent airborne fungal pathogens in the world, A. 333 fumigatus causes invasive aspergillosis (IA) in immunocompromised patients globally (31). In 334 immunocompetent individuals IA is able to be naturally combated by the natural 335 immunosuppressive abilities of the human body (31). One virulence factor presented by A. 336 fumigatus is the ability to produce abounding numbers of spores with conidia resulting to be 337 present in concentrations ranging from 1-100 conidia/m -3 in the air (31). Despite the high 338 prevalence of IA in immunocompromised patients with a high morbidity and even higher 339 mortality, not much is known about A. fumigatus. With this in mind we tested the efficacy of NB-340 201 in vitro with results similar to that observed in C. albicans (table 2) or methicillin-resistant S. 341 aureus (14). Due to the large abundance of conidia present in the air A. fumigatus primarily 342 infects the respiratory tract (32). Thus, in similar fashion to C. neoformans further exploring the 343 efficacy of NB-201 in vivo would be of interest. This could be achieved via an intratracheal 344 infection in a mouse model followed by subsequent treatments of NB-201 formulated as an 345
aerosol. 346
Mucormycosis is a recently emerging opportunistic fungal infection (33). The typical 347 causative agents for mucormycosis fall under the Mucorales family, which include Rhizopus 348 spp., Mucor spp., and others (34). Due to the emergence of immunocompromising diseases 349 such as HIV/AIDS or other medical conditions with lowered immunity there has been an 350 increase in opportunity for fungal infections to afflict patients globally (35, 36) . Mucormycosis 351 presents itself with a mortality rate of ~50% in all mucormycosis cases and an unacceptable 352 >90% mortality in disseminated mucormycosis cases (36) (37) (38) . In the event that patients survive 353 infection they typically suffer from disfiguration due to surgically removing infected tissue; a 354 common way of treating mucormycosis infection aside from treatment with amphotericin B (39). 355
Following the theme of which we have observed previously, NB-201 presented a killing ability 356 comparable to that observed in our C. albicans in vitro experiments. Mucormycosis is typically 357 caused when the acquired spores are inhaled into the body (36, 37) . Although cutaneous 358 infections of mucormycosis in patients undergoing traumatic injury have been reported (36, 40) . 359
It is in this type of cutaneous infection that NB-201 would present itself to be most effective in 360 combating Mucorales infection. 361
Due to the nature of NB-201, the use of it as a topical treatment alternative for fungal 362 infections with little to no drug resistance being developed by the fungi it is killing would be a 363 possibility. Such treatments could include ointments for skin infections, aerosols for infection of 364 the airways and lungs, and even oral washes for possible oral-pharyngeal infections. Previously, NB-201 presented a highly effective antimicrobial potential against various 372 methicillin-resistant S. aureus strains both in vitro and in vivo. In this study we have presented a 373 novel use for the NB-201 nanoemultion formulation that presents killing abilities observed in 374 vitro against 35 different fungi 30 of which are either clinical isolates or antifungal drug resistant 375 strains. We also observed the reduction in inflammation, wound healing, and fungal pathogen 376 clearing abilities of NB-201 in a murine host model (Figure 4 ). Due to the nature of the activity 377 NB-201 presents, there is a minimized chance of drug resistance to develop, thus presenting a 378 novel way to control fungal wound or skin infections. 379 380 381 382
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